NAUT Stock Overview
A development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nautilus Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$3.12 |
| 52 Week Low | US$1.61 |
| Beta | 1.03 |
| 1 Month Change | 9.66% |
| 3 Month Change | -29.82% |
| 1 Year Change | -36.72% |
| 3 Year Change | -53.94% |
| 5 Year Change | n/a |
| Change since IPO | -81.51% |
Recent News & Updates
Recent updates
We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
Jul 27
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 16Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth
Oct 22We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
May 25We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 17Nautilus Biotechnology Q2 2022 Earnings Preview
Aug 01The Take On Nautilus Biotechnology
Jan 17Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point
Jan 07Nautilus Biotechnology: Tapping The Potential Of The Human Proteome
Aug 30Shareholder Returns
| NAUT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.8% | -0.8% | 3.1% |
| 1Y | -36.7% | -1.0% | 23.7% |
Return vs Industry: NAUT underperformed the US Life Sciences industry which returned -1% over the past year.
Return vs Market: NAUT underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| NAUT volatility | |
|---|---|
| NAUT Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NAUT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NAUT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 161 | Sujal Patel | www.nautilus.bio |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system.
Nautilus Biotechnology, Inc. Fundamentals Summary
| NAUT fundamental statistics | |
|---|---|
| Market cap | US$242.34m |
| Earnings (TTM) | -US$70.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs NAUT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAUT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$70.21m |
| Earnings | -US$70.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NAUT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 11:17 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nautilus Biotechnology, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Sykes | Goldman Sachs |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |
| Brandon Couillard | Jefferies LLC |